A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Interventions: Drug: Tiragolumab; Drug: Atezolizumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Sponsor: Hoffmann-La Roche
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
October 13, 2020 /
/ in Oncology